Recent reports have brought to light the dangers associated with stem cell injections, specifically related to Mycobacterium abscessus infections. Three patients developed difficult-to-treat infections after receiving embryonic stem cell injections in Mexico in 2022, highlighting the risks involved in seeking unapproved treatments.
Case Studies
In a study conducted by researchers, two men from Colorado and Arizona acquired M. abscessus infections following donor embryonic stem cell injections for joint pain in Mexico. These patients, identified as Patient B and Patient C, developed infections in various joints after seeking treatment abroad. Additionally, a Colorado woman (Patient A) received stem cell injections for multiple sclerosis and also contracted an M. abscessus infection, emphasizing the widespread risks associated with these procedures.
Genomic Analysis
Researchers performed whole-genome sequencing and phylogenetic analyses on the isolates from patients A and B, identifying distinct core genomes that were not linked to known circulating clones. The findings suggested a common infected source for the patients, potentially related to the products, reagents, or equipment used during the procedure. This highlights the importance of stringent protocols and quality control measures in stem cell treatments to prevent infections.
M. abscessus is an intrinsically drug-resistant bacterium found in water, soil, and dust, making it challenging to treat with conventional antibiotics. Patients who receive injections without proper disinfection or have open wounds are at increased risk of infection by M. abscessus, leading to symptoms such as fever, chills, and muscle aches. The rapid growth and resistance of this bacterium pose significant challenges for healthcare providers in managing these infections.
The FDA does not approve stem cell interventions for arthritis or joint injuries, yet clinics in the U.S. and abroad continue to offer these unproven therapies to vulnerable patients. Despite the lack of scientific evidence supporting the efficacy of stem cell injections for chronic conditions, the allure of alternative treatments persists, leading to potentially harmful consequences for unsuspecting individuals.
The three patients affected by M. abscessus infections are currently receiving ongoing care, underscoring the importance of close monitoring and follow-up for individuals undergoing stem cell treatments. Despite efforts to contact the clinics responsible for the injections, the response has been lacking, highlighting the challenges in regulating and overseeing these procedures. Moving forward, additional genomic sequencing and surveillance will be crucial in identifying and preventing similar cases in the future.
The case studies involving M. abscessus infections following stem cell injections serve as a cautionary tale about the risks associated with unapproved treatments. Healthcare providers, regulatory agencies, and patients alike must remain vigilant in assessing the safety and efficacy of alternative therapies to prevent adverse outcomes and safeguard public health.
Leave a Reply